Abstract
The role of hyperforin in combination anticancer therapy remain unknown. In this study, several doses of combination treatment (paclitaxel and hyperforin) were introduced to the Michigan Cancer Foundation (MCF)-7 cell culture for 24 h. The effectiveness of the drug’s combination effect was determined by the combination index (CI)followed by the anticancer effect through apoptosis, reactive oxygen species (ROS), lactate dehydrogenase (LDH) and caspase 8 assays. It was found that combined doses of paclitaxel (7, 6, 5, 4 µg/mL) and doses of hyperforin (1, 2, 3 and 4 µg/mL) enhanced synergistic growth inhibitory effect. (Hy: 4 µg/mL & Pa: 4 µg/mL) was selected as suitable dose with lowest CI and it significantly induced changes to MCF-7 cell morphology and led to apoptosis with increased in the high level of ROS, LDH and caspase 8 compared to singly treated hyperforin. This study provides the basis for elucidation of combination of hyperforin and paclitaxel on animal models.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.